Chemodynamic and Photothermal Combination Therapy Based on Dual-Modified Metal-Organic Framework for Inducing Tumor Ferroptosis/Pyroptosis

ACS Appl Mater Interfaces. 2022 Jun 1;14(21):24089-24101. doi: 10.1021/acsami.2c00574. Epub 2022 May 19.

Abstract

Single therapy for tumor therapy always exerts limited ability for the constraints on the reaction condition and the unavoidable multidrug resistance, which seriously influences the therapy effect in the clinic. Herein, a combination treatment nanosystem (MP@PI) based on chemodynamic therapy (CDT) and photothermal therapy (PTT) is constructed for triggering ferroptosis/pyroptosis, which is the metal-organic framework (MOF) modified with polydopamine (PDA) and IR820 to loaded with piperlongumine (PL). The MOF and PL respectively served as the iron source and H2O2 source, performing chemodynamic therapy (CDT) for eliciting ferroptosis. Meanwhile the iron source induces pyroptosis in tumor cells. PDA is not only pH responsive to release PL but also CDT-assisted which due to PDA consumes the glutathione to decrease the expression of glutathione peroxide 4. The photosensitizer IR820 exerts photothermal effects under near-infrared light and further facilitates the ferroptosis/pyroptosis. In addation, the MP@PI nanoplatform evokes the immune response in vivo and enhances the antitumor effects further. Overall, MP@PI is a kind of promising cancer therapy strategy through CDT and PTT combination, inducing ferroptosis and pyroptosis.

Keywords: CDT; PTT; ferroptosis; metal−organic framework; pyroptosis.

MeSH terms

  • Cell Line, Tumor
  • Ferroptosis*
  • Glutathione
  • Hydrogen Peroxide
  • Iron
  • Metal-Organic Frameworks* / pharmacology
  • Metal-Organic Frameworks* / therapeutic use
  • Photothermal Therapy
  • Pyroptosis

Substances

  • Metal-Organic Frameworks
  • Hydrogen Peroxide
  • Iron
  • Glutathione